FDA Granted Breakthrough Status to Colorectal Cancer Drug
The designation for telisotuzumab adizutecan was based on clinical trial data showing improved progression-free survival.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Do you trust that FDA breakthrough designations significantly improve patient access to effective new cancer treatments?
The FDA has granted breakthrough therapy designation to telisotuzumab adizutecan in combination with bevacizumab for patients with refractory metastatic colorectal cancer. This status follows clinical trial results demonstrating that the combination significantly extended progression-free survival compared to the standard-of-care.
Why it matters
The designation recognizes the potential of this combination to provide a more effective treatment option for patients who have exhausted traditional therapies like fluoropyrimidine and irinotecan. It aims to accelerate the development and regulatory review process for this promising drug candidate.
In the phase 1 study, patients treated with 2.4 mg/kg of telisotuzumab adizutecan plus bevacizumab achieved a median progression-free survival of 6.8 months. This compares to 4.2 months for those receiving standard-of-care TAS-102 plus bevacizumab.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by regulating the safety and efficacy of medical products.
ESMO Congress
The European Society for Medical Oncology holds an annual congress to showcase the latest clinical research and innovations in cancer treatment.
The details
The FDA also granted breakthrough therapy designation for telisotuzumab adizutecan monotherapy to treat nonsquamous non-small cell lung cancer. The drug is currently being evaluated in the global phase 3 AndroMETa-CRC trial, which compares the combination treatment against standard-of-care protocols.
Timeline
May 29, 2025: Data cutoff date for the phase 1 study M21-404.
2025: Clinical data from the study was presented at the ESMO Congress.
October 7, 2026: The FDA officially granted breakthrough therapy designation.
The Big Picture
This development follows the trajectory established by the AndroMETa-CRC phase 3 trial, which serves as the definitive test for the efficacy of this combination therapy compared to historical treatment standards.
This breakthrough status may shorten the timeline for when this treatment becomes available for patients with refractory metastatic colorectal cancer. Patients should consult their oncologists to understand if current or future clinical trials could be a viable option for their care.
The takeaway
Breakthrough therapy designation represents a critical regulatory milestone that often results in more frequent interactions with the FDA during development. This designation indicates that early evidence suggests the drug may offer a substantial improvement over existing available therapies.
Further reading
Learn more about the latest developments in oncology research in our Cancer section.
More information
View the AndroMETa-CRC phase 3 trial details on the official government portal.
Live Poll
Do you trust that FDA breakthrough designations significantly improve patient access to effective new cancer treatments?
